Menu

Advanced Micro Devices, Inc. AMD

Full chart Compare
Set alert

Price alert · AMD

All alert types
515.21 USD +6.63 (+1.30%)

At closeNov 10, 2026, 7:59 PM EST

524.73 +9.52 +1.85%

After hours · Nov 10, 7:59 PM ET

495.00 Day range 539.25
188.22 52-week range 658.52
YTD
+140.57%
1 year
+111.17%

Discussion (7890)

Sign in to join the discussion

NeMo AMD 3 years ago #3401

Always drops even in good earnings and then pops in a few days after!!

Kman AMD 3 years ago #3403

$AMD Total gift at this price. ????

Kman AMD 3 years ago #3405

$AMD Algos keeping this down today before earnings tomorrow. Earnings will be big and a beat and raise. $110+ tomorrow $200 by February

Kman AMD 3 years ago #3406

$AMD This stock will be $150/share within a year

Stuart Spencer AMD 3 years ago #3408

It’s curious how hard someone ran down AMD on Wednesday -7%. Seems to me that someone wanted to get in at a much lower price before earnings. Seriously no bounce all day. Then today strong all day with almost no pull back. How is this even possible without some kind of manipulation. This is how I loose confidence in these markets.

VICKY HANUKA AMD 3 years ago #3410

$PTC Therapeutics(PTCT.US)$ ?????????????? Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi -- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.